Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax (NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue expectations. The company ...

Novavax said it was eligible to receive royalties in high teens to low twenties percent on Sanofi sales, up to $350 million ...

Novavax NVAX incurred a fourth-quarter 2024 ... A regulatory filing is currently under the FDA’s review seeking full approval for the COVID-19 vaccine, with a final decision expected in April.

Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

The Iowa Senate bill alters a proposal that would have penalized administering gene-based vaccines including the COVID-19 ...

Every fall and winter, the United States sees an uptick in the number of people who fall ill to influenza and other seasonal diseases. This flu season typically stretches from October to ...

The NIH says funding cuts would save it billions of dollars a year. D.C.-area industry and academic leaders say it would cripple R&D.